| Literature DB >> 33817720 |
Cristina Strobescu-Ciobanu1, Simona Eliza Giuşcă, Irina Draga Căruntu, Cornelia Amălinei, Andreea Rusu, Elena Cojocaru, Radu Florin Popa, Cristian Dumitru Lupaşcu.
Abstract
Atherosclerosis (ATS) is still considered as a major, global health problem. For a deeper understanding of its pathogenesis, in the last years the research was translated from tissue visible events to molecular mechanisms. Osteopontin (OPN) and osteoprotegerin (OPG) are two molecules that have been associated with the initiation and progression of ATS lesions. The aim of our study was to assess the OPN and OPG expression in advanced stages of carotid ATS, to analyze the correlation between these markers and the ultrasonographic plaque properties, pointing out the identification of possible patterns that can predict plaque vulnerability and risks of restenosis. The study group comprised 49 consecutive patients (38 males and 11 females) diagnosed with carotid stenotic lesions by using ultrasonography. The carotid endarterectomy specimens were standardly processed for histopathological and immunohistochemical exams. The OPN and OPG expression was semi-quantitatively assessed. Our results sustained the relationship between histological American Heart Association (AHA) type and ultrasonographic classification (echogenic versus echolucent) (p<0.001). The semi-quantitative analysis showed that in most cases (31 plaques) OPG and OPN had opposite expressions, whereas in the remaining cases (18 plaques) the expression was similar. There were no correlations between low versus high expression of intra-plaque OPN and OPG (p=0.335). We found significant correlation for OPN and plaque echogenicity (p=0.011), but not for OPG (p=0.079). OPN expression (low versus high) was correlated with plaque type (stable versus unstable) (p=0.036), plaque ulceration (p=0.009) and inflammation (p<0.001). OPG expression (low versus high) did not reveal statistically significant differences with plaque type (stable versus unstable) and vulnerability plaque parameters, respectively. OPG and OPN co-exist in carotid atherosclerotic plaque demonstrating a modulatory role in inflammatory and calcification processes. OPG is strongly expressed in stable, calcified plaques, while OPN is poorly expressed in calcified plaques and in plaques without hemorrhage, ulceration, inflammation, or necrosis. Starting from the molecular mechanisms, further studies of biomarkers are important to identify new therapeutic resources meant to prevent and treat vascular calcification.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33817720 PMCID: PMC8112796 DOI: 10.47162/RJME.61.3.17
Source DB: PubMed Journal: Rom J Morphol Embryol ISSN: 1220-0522 Impact factor: 1.033
Epidemiology, clinical characteristics, and pre-operatory treatment
|
|
|
|
|
|
|
|
|
▪ Male |
38 |
77.5% |
|
▪ Female |
11 |
22.5% |
|
|
|
|
|
▪ TIA |
19 |
38.7% |
|
▪ Stroke |
18 |
36.7% |
|
▪ |
3 |
6.1% |
|
▪ Absent |
9 |
18.4% |
|
|
|
|
|
▪ Hypertension |
37 |
75.5% |
|
▪ Dyslipidemia |
20 |
40.8% |
|
▪ Diabetes mellitus |
15 |
30.6% |
|
▪ Active smokers |
10 |
20.4% |
|
▪ Peripheral arterial disease |
15 |
30.6% |
|
|
|
|
|
▪ ASA/platelet aggregation inhibitors before admission |
40 |
81.6% |
|
▪ HMG-CoA reductase inhibitors before admission |
48 |
97.9% |
ASA: Acetylsalicylic acid; HMG-CoA: β-Hydroxy-β-methylglutaryl coenzyme A; TIA: Transient ischemic attack
Figure 1Low OPN expression in the periphery of the lipid core (IHC staining with anti-OPN antibody, ×100). IHC: Immunohistochemical; OPN: Osteopontin
Figure 2Strong OPN expression in the periphery of the calcification area, in foamy macrophages, fibroblasts, and inflammatory cells of the plaque (IHC staining with anti-OPN antibody, ×100). IHC: Immunohistochemical; OPN: Osteopontin
Figure 3Strong OPG expression in the fibro-lipid plaque (lipid core, smooth muscle cells, fibroblasts, extracellular matrix); smooth muscle cells OPG positive in the media (IHC staining with anti-OPG antibody, ×100). IHC: Immunohistochemical; OPN: Osteoprotegerin
Figure 4Strong OPG expression in the lipid core, adjacent to cholesterol crystals, in the extracellular matrix and intracellular matrix resident cells (fibroblasts) or migrated cells (inflammatory elements) (IHC staining with anti-OPG antibody, ×100). IHC: Immunohistochemical; OPN: Osteoprotegerin
OPN and OPG expression in correlation to morphological parameters
|
|
|
|
|
| |||
|
|
|
|
| ||||
|
Calcification |
|
6 (60%) |
4 (40%) |
0.370 |
2 (20%) |
8 (80%) |
0.339 |
|
|
29 (74.4%) |
10 (25.6%) |
14 (35.9%) |
25 (64.1%) | |||
|
Hemorrhage |
|
31 (73.8%) |
11 (26.2%) |
0.366 |
15 (35.7%) |
27 (64.3%) |
0.263 |
|
|
4 (57.1%) |
3 (42.9%) |
1 (14.3%) |
6 (85.7%) | |||
|
Ulceration |
|
30 (81.1%) |
7 (18.9%) |
0.009 |
14 (37.8%) |
23 (62.2%) |
0.174 |
|
|
5 (41.7%) |
7 (58.3%) |
2 (16.7%) |
10 (83.3%) | |||
|
Inflammation |
|
29 (90.6%) |
3 (9.4%) |
<0.001 |
11 (34.4%) |
21 (65.6%) |
0.724 |
|
|
6 (35.3%) |
11 (64.7%) |
5 (29.4%) |
12 (70.6%) | |||
|
Necrosis |
|
27 (75%) |
9 (25%) |
0.357 |
13 (36.1%) |
23 (63.9%) |
0.390 |
|
|
8 (61.5%) |
5 (38.5%) |
3 (23.1%) |
10 (76.9%) | |||
|
Morphologically stable plaques |
28 (80%) |
7 (20%) |
0.036 |
13 (37.1%) |
22 (62.9%) |
0.289 | |
|
Morphologically unstable plaques |
7 (50%) |
7 (50%) |
3 (21.4%) |
11 (78.6%) | |||
OPG: Osteoprotegerin; OPN: Osteopontin